Study Summary
This is a Phase 1, single-arm, single-center, open-label study to evaluate the safety and effectiveness of NKG2D-based CAR-T cells infusion in the treatment of advanced NKG2DL+ solid tumors.
Want to learn more about this trial?
Request More InfoInterventions
KD-025 cell injectionDRUG
This is an open-label, dose escalation/expansion study to assess the safety, tolerability, and efficacy of KD-025 cell infusion in patients with advanced NKG2DL+ solid tumor. In this study,the enrollment of the patients must meet the inclusion and exclusion criteria . All subjects will be undergo screening, pre-treatment (cell product preparation;lymphodepleting chemotherapy), treatment and follow up
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Cancer hospital Chinese Academy of Medical Sciences | Beijing | Beijing Municipality | China |